Drug intelligence / Profile preview

nanaomycin d

Development stage
Unknown
Lead developer
Streptomyces
Modality
RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
01

Overview

Nanaomycin D is a small molecule antibiotic belonging to the benzoisochromanequinone class of polyketides and is produced by certain Streptomyces species such as Streptomyces rosa[1][2][3]. It exhibits antibacterial activity and has been studied primarily as an experimental compound rather than a clinically approved drug[1][8]. Nanaomycin D’s mechanism of action is not fully elucidated but it acts as an antibiotic with reported activity against bacteria and fungi[8][9]. It has also been listed in pharmaceutical compound libraries for research purposes but lacks clinical approval or established therapeutic indications in humans[1].

Other names
(11R,15S,17S)-4-hydroxy-17-methyl-12,16-dioxatetracyclo[8.7.0.03,8.011,15]heptadeca-1(10),3(8),4,6-tetraene-2,9,13-trione(3aS,5S,11bR)-7-hydroxy-5-methyl-3,3a,5,11b-tetrahydro-2H-benzo[g]furo[3,2-c]isochromen-2,6,11-trioneNANAOMYCIN D
02

Targets

GlmS (Glucosamine-6-phosphate synthase)Nanaomycin D reductase

Beyond the preview

Go deeper on nanaomycin d.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nanaomycin d.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call